Related LVS 5 Trends U.S. Casino Investors Need To Watch Deutsche Bank Says Buy MGM Following SotP Analysis, 'Encouraging' Q4 Metrics Macau at the crossroads (Seeking Alpha)
Related Benzinga's Top Upgrades Morgan Stanley Revises Triple-Net REIT Ratings Prior To Q2 Earnings
One of the more unique technical analysis metrics used to determine buy and sell signals is Parabolic SAR. Developed by Welles Wilder in 1978, the “SAR” stands for “stop and reverse.”
Top 5 Casino Stocks To Own For 2018: Concord Medical Services Holdings Limited(CCM)
Advisors’ Opinion:
- [By Jim Robertson]
On Wednesday,our Under the Radar Moversnewsletter suggested going long on small cap China basedhealthcare equipment and management services stock Concord Medical Services Holdings Ltd (NYSE: CCM):
Top 5 Casino Stocks To Own For 2018: Towerstream Corporation(TWER)
Advisors’ Opinion:
- [By Lisa Levin]
Towerstream Corporation (NASDAQ: TWER) shares were also up, gaining 9 percent to $3.49. Towerstream is scheduled to report Q2 financial results on August 9, 2016.
Top 5 Casino Stocks To Own For 2018: Fiat Chrysler Automobiles N.V.(FCAM)
Advisors’ Opinion:
- [By WWW.THESTREET.COM]
The showstopper by far in the early going is Waymo’s self-driving minivan (pictured below) in partnership with Fiat Chrysler (FCAM) . Waymo’s ultimate mom-mobile, coming from a business that was spun-off from Google’s parent company Alphabet Inc. (GOOG) last month, is equipped with self-driving sensors and vision systems.
Top 5 Casino Stocks To Own For 2018: Intercept Pharmaceuticals, Inc.(ICPT)
Advisors’ Opinion:
- [By Paul Ausick]
Intercept Pharmaceuticals Inc. (NASDAQ: ICPT) dropped more than 17% Friday to post a new 52-week low of $60.97 after closing Thursday at $73.70. The 52-week high is $172.75. Volume of more than 10 million shares traded was about 12 times the daily average. The FDA on Thursday issued a warning letter on the company’s liver disease treatment.
- [By Peter Graham]
Small cap liver biopharmaceutical stock Intercept Pharmaceuticals Inc (NASDAQ: ICPT) reportedQ2 2017 earnings before the market opened on Monday with both the top and bottom lines beating expectations plus the Companyreported that amid-stage clinical trial met its primary endpoint; but sharesended the day down13.26%. Intercept Pharmaceuticals recognized $30.4 million of net sales of Ocaliva for Q2 2017 versus $75k and a net loss of $86.6 million versus a net loss of $77.3 million. Ocaliva was approved by the U.S.FDA in May 2016 for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults with an inadequate response to UDCA or as monotherapy in adults unable to tolerate UDCA. As of June 30, 2017,the Companyhad cash, cash equivalents and investment securities available for sale of approximately $550.3 million versus$689.4 million as of December 31, 2016. The CEO commented:
Top 5 Casino Stocks To Own For 2018: Monolithic Power Systems, Inc.(MPWR)
Advisors’ Opinion:
- [By Lee Jackson]
Monolithic Power Systems Inc. (NASDAQ: MPWR) has a diverse market that includes communications, gaming and computing to continue to drive its growth, all markets that will pay a premium for its technology. The list of tech companies that use its chips is impressive. Deutsche Bank has a $30 target, the same as the consensus target.
